Huikwang Corporation AI Stock Analysis
Huikwang Corporation (6508) AI Stock Analysis
Huikwang Corporation
(TPEx:6508)
Huikwang scores in the middle of the range. The dominant drag is deteriorating earnings power: revenue is down over 40% from its 2022 peak, net margin has thinned to 1.6% and ROE has fallen below 1%, while a P/E of 27.3 leaves little valuation cushion. Offsetting this is genuine downside protection — a near debt-free balance sheet with equity funding 85% of assets, and consistent free cash flow of NT$191m that comfortably exceeds reported profits and supports the 1.9% dividend. Technicals are mildly supportive on a longer horizon, with the price above its 100- and 200-day averages, though short-term momentum has stalled. The stock is low-risk financially but needs a volume and margin recovery before the rating can improve.
Huikwang Corporation (6508) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.36B
- Dividend Yield
- 1.83%
- Average Volume (3M)
- 61.87K
- Price to Earnings (P/E)
- 26.7
- Beta (1Y)
- 0.02
- Revenue Growth
- -14.31%
- EPS Growth
- 315.97%
- Country
- TW
- Employees
- 140
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals
Huikwang Corporation Business Overview & Revenue Model
Company Description
Huikwang Corporation, founded in 1954 and headquartered in Tainan, Taiwan, is engaged in a broad spectrum of industrial activities. The company specializes in the full production lifecycle—from manufacturing and processing to packaging and trading—of...
Huikwang Corporation Financial Statement Overview
Summary
A tale of two halves. The balance sheet is a fortress (score 79): debt-to-equity of just 0.05, debt cut from NT$452m in 2020 to NT$115m, and equity funding ~85% of assets. Cash flow is also healthy (score 71), with NT$205m operating cash flow and NT$191m free cash flow (~13% of sales), far exceeding reported net income and easily covering the modest debt load. The income statement, however, is weak (score 36): revenue has fallen more than 40% from its 2022 peak to NT$1.42bn, net income collapsed from NT$314m to NT$23m, net margin compressed to 1.6% and ROE to under 1%. Gross margin has held near 22%, but fixed costs and weaker volumes are crushing operating leverage.
Income Statement
36NegativeBalance Sheet
79PositiveCash Flow
71Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.35B | 1.42B | 1.48B | 1.53B | 2.49B | 2.09B |
| Gross Profit | 316.37M | 318.81M | 314.51M | 339.06M | 607.82M | 543.41M |
| EBITDA | 92.94M | 105.92M | 167.76M | 174.67M | 454.13M | 527.38M |
| Net Income | 87.90M | 23.02M | 92.57M | 90.92M | 314.46M | 329.08M |
Balance Sheet | ||||||
| Total Assets | 2.78B | 2.81B | 2.90B | 2.97B | 3.26B | 3.18B |
| Cash, Cash Equivalents and Short-Term Investments | 808.35M | 791.38M | 724.42M | 675.38M | 611.20M | 672.98M |
| Total Debt | 41.24M | 115.45M | 134.94M | 275.62M | 348.31M | 332.93M |
| Total Liabilities | 336.99M | 412.10M | 446.53M | 551.62M | 710.83M | 730.78M |
| Stockholders Equity | 2.44B | 2.40B | 2.45B | 2.42B | 2.55B | 2.45B |
Cash Flow | ||||||
| Free Cash Flow | 176.07M | 190.98M | 180.36M | 418.86M | 119.88M | -104.01M |
| Operating Cash Flow | 176.86M | 205.37M | 211.78M | 438.42M | 136.12M | -86.76M |
| Investing Cash Flow | -77.06M | -64.67M | -28.60M | -15.06M | 141.14M | -61.36M |
| Financing Cash Flow | -157.17M | -126.90M | -144.32M | -361.53M | -247.00M | -276.28M |
Huikwang Corporation Peers Comparison
Overall Rating
TW:124057Neutral- TW:650857Neutral
TW:471437Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1240 | 57Neutral | TWD 2.55B | 11.61 | ― | 5.32% | 5.31% | -6.78% |
| TW:6508 | 57Neutral | TWD 2.34B | 26.65 | ― | 1.83% | -14.31% | 315.97% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4714 | 37Underperform | TWD 2.37B | -14.02 | ― | 1.75% | 74.42% | -247.01% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6508 | Huikwang Corporation | 27.25 | 3.71 | 15.77% | |
| TW:1240 | Morn Sun Feed Mill Corp. | 53.70 | 1.77 | 3.40% | |
| TW:4714 | U-Best Innovative Technology Co.,Ltd | 10.80 | -6.12 | -36.17% | |
| TW:6936 | Vetnostrum Animal Health Co., Ltd. | 31.80 | -1.47 | -4.41% | |
| TW:7850 | Protect Animal Health Incorporation | 21.50 | -13.65 | -38.83% | |
| TW:7860 | Teh Seng Pharmaceutical Mfg Co Ltd | 77.80 | 5.13 | 7.07% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026